Should I Buy TXMD? TXMD 2026 Analysis

Should You Buy TherapeuticsMD Inc (TXMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.300

1 Day change

52 Week Range

2.950

Analysis Updated At

2026/01/26

TherapeuticsMD Inc (TXMD) is not a strong buy for a beginner investor with a long-term strategy at this moment. While there are some positive indicators like insider buying and bullish technical indicators, the overbought RSI, lack of significant news catalysts, and weak financial performance in the latest quarter suggest caution. Additionally, the absence of Intellectia Proprietary Trading Signals and the high implied volatility in options data further support a hold stance.

Technical Analysis

The stock shows bullish momentum with MACD above zero and positively expanding, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the RSI at 90.746 indicates the stock is overbought. Key resistance levels are at 2.571 and 2.738, with support at 2.029 and 1.861.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low open interest put-call ratio suggests bullish sentiment, but the high option volume put-call ratio indicates significant bearish activity in the short term. Implied volatility is extremely high at 590.95, suggesting elevated risk.

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has surged by 399.50% over the last month, indicating confidence from company insiders. The MACD and moving averages are bullish, reflecting positive technical momentum.

Neutral/Negative Catalysts

The RSI indicates the stock is overbought, suggesting a potential pullback. Financial performance in Q3 2025 shows a significant decline in net income (-124.96% YoY) and EPS (-120.00% YoY). Additionally, there is no recent news or significant trading trends from hedge funds. The stock has a 40% chance of declining in the next day and week based on candlestick analysis.

Financial Performance

In Q3 2025, revenue increased by 43.33% YoY to $784,000, but net income dropped by -124.96% YoY to $152,000, and EPS fell by -120.00% YoY to 0.01. Gross margin remained flat at 100%. While revenue growth is a positive sign, the sharp decline in profitability is a concern.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for TXMD.

Analyst Rating

Wall Street analysts forecast TXMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXMD is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy